CLOs on the Move

Genactis

www.genactis.com

 
Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Verséa Health

Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.

Sonovion Pharmaceuticals

Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elixinol Global

The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.

Reditus Laboratories

Reditus Laboratories is a full-service laboratory company. We are committed to providing our client physicians with top-tier, accurate anatomical and clinical pathology services.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.